Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 18;16(7):e64849.
doi: 10.7759/cureus.64849. eCollection 2024 Jul.

Ethnic Differences, Lung Cancer Risk, and Association of NRF2 Gene Polymorphism with Gemcitabine-Based Chemotherapy

Tirumalasetty Devika  1 , Ganesapandian Mahalakshmi  2 , K Mythili  3 , Katiboina Srinivasa Rao  4 , Suresh Kumar Srinivasamurthy  5 , Dubashi Biswajit  6 , Deepak Gopal Shewade  7
Affiliations

Ethnic Differences, Lung Cancer Risk, and Association of NRF2 Gene Polymorphism with Gemcitabine-Based Chemotherapy

Tirumalasetty Devika et al. Cureus. .

Abstract

Introduction: The cancer burden is rising every year. Lung cancer is one of the most common cancers and non-small cell lung cancer is the most common type. Chemotherapy based on platinum drugs and third-generation nucleoside anti-metabolites such as gemcitabine are used widely. Gemcitabine has a complex metabolic pathway, with many mechanisms contributing to its cytotoxicity. Derangements in the metabolic pathway genes contribute to drug resistance and toxicity with this drug. Association studies including these genetic polymorphisms in the metabolic pathway, clinical outcomes, and cancer risk reported inter-individual differences. Thus, the aim of this study was to ascertain the role of these genetic variants in South Indian cancer patients treated with gemcitabine-based therapy.

Methods: The study was done with 184 healthy volunteers for frequency establishment and 123 cancer patients were treated with gemcitabine-based chemotherapy for response and toxicity assessment. The participants were aged 18-65 years and resided in the southern states of India. DNA extraction was done from the leukocyte fraction of the blood by phenol-chloroform extraction procedures and genotyping was done by reverse transcription-polymerase chain reaction (RT-PCR) techniques to identify DNA repair gene polymorphisms. Tumor response was determined using Response evaluation criteria in solid tumors (RECIST) guidelines and toxicity using Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The patients were followed up for survival analysis.

Results: The minor allele frequency of the single nucleotide polymorphism (SNP) NRF2-617 C>A (rs6721961) in the healthy population was 12.8%. SNPs were in Hardy-Weinberg equilibrium (p>0.05). Gender-based differences were not observed with the studied SNP in the healthy population and the lung cancer patients. These frequencies of NRF2 were found to be similar when compared to EUR (European) and all the South Asian subpopulations. They are significantly divergent compared to AFR (African), AMR (American), and EAS (East Asian) populations. The minor allele frequency in cancer patients was found to be 14.2% and the lung cancer risk with the SNP studied could not be detected. There was no association found with the response, toxicity, and survival among lung cancer patients.

Conclusion: NRF2, being a multifaced molecule, did not show a significant association with lung cancer risk, response, and toxicity in patients with gemcitabine-based chemotherapy.

Keywords: chemotherapy; gemcitabine; lung cancer; nrf2; polymorphisms; rs6721961 c>a; south indians.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Institute Ethics Committee (Human Studies), JIPMER, Puducherry, India issued approval JIP/IEC/2014/4/310 dated June 27, 2014. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Kaplan-Meier curve of NRF2 rs 6721961 C>A for the lung cancer patients (N=123)
HR: hazard ratio; Cum Survival: cumulative survival
See this image and copyright information in PMC

References

    1. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Itoh K, Chiba T, Takahashi S, et al. Biochem Biophys Res Commun. 1997;236:313–322. - PubMed
    1. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Rushmore TH, Kong AN. Curr Drug Metab. 2002;3:481–490. - PubMed
    1. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Nguyen T, Yang CS, Pickett CB. Free Radic Biol Med. 2004;37:433–441. - PubMed
    1. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Fahey JW, Kensler TW. Chem Res Toxicol. 2007;20:572–576. - PMC - PubMed
    1. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Kensler TW, Wakabayashi N, Biswal S. Annu Rev Pharmacol Toxicol. 2007;47:89–116. - PubMed

LinkOut - more resources